You are here: Home » International » News » Companies
Pakistan eyes IMF board's crucial meeting on bailout package today
Focused on getting self-driving Teslas in wide release by year-end: Musk
Business Standard

Lupin gets USFDA approval to market generic cancer treatment drug

Lupin on Monday said it has received a tentative approval from the US health regulator to market Dasatinib tablets, used to treat certain types of cancer, in America

Topics
Lupin | US FDA | cancer treatment

Press Trust of India  |  New Delhi 



pharma, medicines, drugs
Representative Image

on Monday said it has received a tentative approval from the US health regulator to market Dasatinib tablets, used to treat certain types of cancer, in America.

The company in partnership with Pharmascience Inc. has received approval from the US Food and Drug Administration (FDA) for Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, it said in a statement.

The Mumbai-based drug maker's product is a generic version of Bristol-Myers Squibb Company's Sprycel tablets.

As per IQVIA MAT data, Dasatinib tablets had an estimated annual sale of USD 1,569 million in the US.

Shares of settled at Rs 662.50 apiece, up 1.49 per cent on the BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Mon, August 29 2022. 17:15 IST

RECOMMENDED FOR YOU

.